Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 16:41:11 GMT 2023
by
admin
on
Sat Dec 16 16:41:11 GMT 2023
|
Protein Type | MONOCLONAL ANTIBODY |
Protein Sub Type | IGG1 |
Sequence Origin | HUMANIZED MOUSE |
Sequence Type | COMPLETE |
Record UNII |
K16AIQ8CTM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type | ||
---|---|---|---|
|
Alternative Definition |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
284409
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
||
|
WHO-VATC |
QL01XC13
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
||
|
NCI_THESAURUS |
C155711
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
||
|
WHO-ATC |
L01XC13
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
||
|
NDF-RT |
N0000175661
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
||
|
FDA ORPHAN DRUG |
400713
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8380
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
Pertuzumab
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
4957
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
PERJETA
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | APPROVED JUNE 2013 | ||
|
100000078567
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
C485206
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
K16AIQ8CTM
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL2007641
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
K16AIQ8CTM
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
C38692
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
1298944
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
380610-27-5
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
OO-59
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
SUB16455MIG
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
8141
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
PERTUZUMAB
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
m8568
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB06366
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY | |||
|
5046
Created by
admin on Sat Dec 16 16:41:12 GMT 2023 , Edited by admin on Sat Dec 16 16:41:12 GMT 2023
|
PRIMARY |
From | To |
---|---|
1_22 | 1_96 |
1_146 | 1_202 |
1_222 | 3_214 |
1_228 | 2_228 |
1_231 | 2_231 |
1_263 | 1_323 |
1_369 | 1_427 |
2_22 | 2_96 |
2_146 | 2_202 |
2_222 | 4_214 |
2_263 | 2_323 |
2_369 | 2_427 |
3_23 | 3_88 |
3_134 | 3_194 |
4_23 | 4_88 |
4_134 | 4_194 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
HER dimerization inhibitor
BINDING
|
||
|
SUB_CONCEPT->SUBSTANCE |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
LABELED -> NON-LABELED |
|
||
|
INHIBITOR -> TARGET |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
MOL_WEIGHT:SEQUENCE(CALCULATED) | CHEMICAL |
|
||||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Molecular Formula | CHEMICAL |
|
||||
Biological Half-life | PHARMACOKINETIC |
|
|
|||